NPHC, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it is the recipient of a $244,479 grant under the Qualifying Therapeutic Discovery Project (QTPD) Program. Nutra Pharma plans to use the grant proceeds to support additional clinical work on its pain treatments.

“It is an honor to receive this grant and to be recognized by the United States Federal Government for our work developing novel analgesics,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We intend to use the proceeds from this grant to support our ongoing clinical development program for our pain relievers, which include Cobroxin and Nyloxin,” he added.

The QTDP Program was enacted in 2010 by the United States Congress as part of the Patient Protection and Affordable Care Act. To be eligible for the grant, a project must demonstrate potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com